Procedure: USP <61> Microbial Enumeration Tests

USP General Chapter <61> Microbial Enumeration Tests provides harmonized, validated methods for quantifying viable aerobic microorganisms. While formally intended for non-sterile pharmaceutical products, the methods are widely applied in biologics for raw materials, bulk drug substances (e.g., mRNA), and in-process controls of sterile drug products (e.g., AAV prior to sterile filtration). The test determines the number of colony-forming units (CFUs) in a sample, a key indicator of microbiological quality. USP <61> is often performed in conjunction with USP <62> (specified microorganisms) and serves as a fundamental part of the microbiological control strategy in CMC.

<61> = enumeration.

<62> = specified organisms.

<71> = sterility.

Legacy: Basic plating techniques have been the foundation of microbiology for over a century. Early methods were often non-standardized.

Current Standard: The harmonized methods described in USP <61>, Ph. Eur. 2.6.12, and JP 4.05 are the global standard. They include Membrane Filtration, Pour Plate, and Spread Plate methods, which are validated and universally accepted by regulatory agencies.

Future: The industry is slowly moving towards Rapid Microbiological Methods (RMMs), such as ATP bioluminescence or automated flow cytometry, which can provide results in hours or days instead of weeks. However, the culture-based methods in USP <61> remain the definitive "gold standard" against which RMMs must be validated.

Membrane Filtration (preferred for filterable/biologics): Pass a defined, appropriately diluted sample through a 0.45 µm sterile membrane; place the membrane on SCDA (bacteria) or SDA (fungi); incubate.
Plate Counts (pour/spread): For non-filterable/solid matrices, inoculate molten agar (pour) or spread onto solid agar (spread); incubate.
Incubation: Typically TAMC 30–35 °C for 48–72 h; TYMC 20–25 °C for 5–7 d (validate per product).
Enumeration: Count colonies; calculate CFU per g or mL using dilution and sample volume.

Use dilutions to achieve countability (e.g., 30–300 colonies for plates). For membrane filtration, count total colonies on the filter. Report as CFU/mL or CFU/g. When no colonies are observed, report “< LOD” based on the volume/mass tested. Non-sterile oral examples (e.g., TAMC NMT 10³ CFU/g; TYMC NMT 10² CFU/g) do not apply to biologics; for mRNA DS/AAV IPC use process-/product-specific limits justified by risk assessment.

Compendial Method: Globally harmonized and accepted by all major regulatory agencies.

Detects Viable Organisms: As a culture-based method, it only detects living microorganisms capable of growth, which is the primary concern for product safety.

Cost-Effective: The materials and equipment are relatively inexpensive compared to rapid methods.

Extremely Slow: Results can take 5-7 days or longer, creating a significant delay in product release.

Labor-Intensive: Requires skilled microbiologists performing meticulous aseptic techniques.

Detects Only Culturable Organisms: It will not detect "viable but non-culturable" (VBNC) organisms or microbes that cannot grow on the specific media used.;  inability to detect mycoplasma (which requires separate testing).

Low Precision: Microbiological testing is inherently variable compared to chemical assays.

Perform Method Suitability (recovery/neutralization) with low inocula (<100 CFU) of specified microorganisms to demonstrate that product matrix and any antimicrobial properties are neutralized/diluted and do not inhibit recovery. For biologics, excipients (e.g., surfactants, buffers) can inhibit recovery—optimize neutralizers and rinse steps accordingly.

Reference Strains: The method uses specific, standardized strains of microorganisms obtained from official culture collections (e.g., ATCC). Examples include Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis.

Growth Media: The composition of the growth media is strictly defined in the pharmacopeia to ensure consistent results.

Non-Sterile Products: Release testing for orals/topicals.

Raw Materials & Excipients: Broadly applied.

mRNA DS: Confirms bulk DS has acceptably low microbial load prior to aseptic DP formulation.

AAV DP – IPC: Confirms low microbial load immediately prior to sterile filtration, supporting sterility assurance.

Biologics (general): Complements USP <71>; bioburden control reduces sterility test failure risk.